Weight loss peptides and medications
Losing weight is less about willpower than about biology: hunger hormones, blood sugar swings, and metabolism all push back. These articles look at the weight loss peptides and medications researchers study — how they work, what results have been measured, and what a realistic plan looks like alongside food and movement.
Nothing here is a shortcut or a guarantee. Medication is one tool, prescribed only when a licensed provider decides it fits your situation. Every article below is specific about what was measured and in whom.
81 articles on this topic
-
Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
Does Insurance Cover Tirzepatide? 2026 Guide
Insurance may cover Mounjaro for type 2 diabetes, while Zepbound coverage for obesity or sleep apnea depends on the plan. Compounded tirzepatide is generally self-pay.
-
Tirzepatide vs Retatrutide: How They Compare
Tirzepatide is a dual GIP/GLP-1 agonist with completed phase 3 trials and approved U.S. indications. Retatrutide is an investigational triple agonist that cannot be prescribed here yet — and that, not potency, is the difference that matters.
-
Is Semaglutide Safe? What the Evidence Shows
Semaglutide has years of trial data and a defined risk profile, but safe is not universal. Eligibility depends on personal history, other medicines, monitoring and exactly what product is dispensed.
-
Tirzepatide Weight Loss Results by Month
In SURMOUNT-1, average weight loss reached 15.0% to 20.9% at 72 weeks, depending on dose. The first month was only the initiation phase, and results varied widely.
-
Does Semaglutide Cause Hair Loss?
In the pooled 68-week trials, hair loss was reported by 3% of adults on semaglutide 2.4 mg against 1% on placebo. Telogen effluvium after fast weight loss explains it better than any proven effect on the follicle.
-
Semaglutide for Type 2 Diabetes: What Trials Show
Brand semaglutide is approved for glycemic control in adults with type 2 diabetes, and the trial record now runs past blood sugar into heart and kidney outcomes. Compounded semaglutide is a different thing again — here is what separates them.
-
Microdosing Semaglutide: What the Evidence Says
A slower climb can be a tolerability strategy. Staying indefinitely on a fraction of a studied dose is a different idea, and the evidence for it is not there yet.
-
How Does Semaglutide Work? Four Effects Explained
Semaglutide activates one receptor but produces coordinated signals in the pancreas, stomach and brain. Its engineered C18 side chain keeps those signals available for about a week.
-
How to Get Semaglutide Prescribed
You can get semaglutide through primary care, a specialist clinic, licensed telehealth or a manufacturer-supported route. Every legitimate path requires medical review before a pharmacy dispenses it.
-
Does Tirzepatide Cause Hair Loss?
In the pivotal 72-week obesity trials, hair loss was reported by about 3%–7% of tirzepatide groups versus about 1% with placebo. Weight-loss-related telogen effluvium is the leading explanation, but a direct drug effect has not been ruled out.
-
Compounded Semaglutide: What It Is in 2026
Compounded semaglutide is a patient-specific prescription, not a generic Ozempic or Wegovy. The ingredient form, dosing label, and post-shortage rules all matter.
-
Get Tirzepatide Online With a Prescription
Getting tirzepatide online still requires a prescription. The legitimate routes all end at the same checkpoint: an authorized clinician reviews your case before a licensed pharmacy dispenses anything.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
AOD-9604 Peptide: Fat-Loss Hype vs the Record
Six placebo-controlled trials in 893 obese adults — capped by a 536-subject study that missed its endpoints — ended AOD-9604's drug development in 2007.
-
Tirzepatide vs Semaglutide: The Head-to-Head Data
In the SURMOUNT-5 trial, adults with obesity but without diabetes averaged 20.2% body-weight loss on tirzepatide and 13.7% on semaglutide over 72 weeks.
-
What Does Tesamorelin Do?
In 26-week Phase 3 trials, daily tesamorelin reduced visceral abdominal fat by 10.9–15.4% in adults with HIV-associated lipodystrophy while placebo groups gained fat.
-
Tirzepatide Clinical Trials: What the Data Show
Two phase 3 programmes, a cardiovascular outcome trial that reported in December 2025, and more than 18,000 participants — here is what the published evidence actually shows, dose by dose.
-
MOTS-c Peptide Benefits: Rodent Depth, Human Hints
MOTS-c is a peptide your mitochondria encode themselves — and it is studied for how cells handle fuel. The rodent evidence runs deep; the human evidence is just beginning.
Page 4 of 5 · 81 articles